Summary:
In diabetic patients undergoing off-pump coronary artery bypass grafting (OPCABG), intraoperative dexmedetomidine infusion at 0.5 µg/kg/h significantly reduced glucose variability, C-reactive protein (CRP) levels, and insulin requirements compared to saline placebo infusion, though it was associated with no significant difference in interleukin-6 (IL-6) levels and no major reported side effects.
| PICO | Description |
|---|---|
| Population | Adult diabetic patients scheduled for off-pump coronary artery bypass grafting (OPCABG). |
| Intervention | Continuous intraoperative dexmedetomidine infusion at 0.5 µg/kg/h. |
| Comparison | Placebo group receiving equivalent volume of normal saline infusion. |
| Outcome | Dexmedetomidine significantly improved glucose variability (GV: 14.38 ± 3.45 vs. 16.44 ± 4.63, P = 0.042), reduced mean insulin requirement (0.88 ± 0.59 U/h vs. 1.38 ± 0.63 U/h, P = 0.001), and decreased CRP at 12 h (1.51 ± 1.13 vs. 2.6 ± 2.83 mg/dL, P = 0.012) and 24 h (10.19 ± 4.56 vs. 16.71 ± 6.45 mg/dL, P < 0.001). IL-6 levels were comparable across both groups. |
Source: Kanupriya Goel, et al. “Glucose Variability IN Diabetic Patients Receiving DEXmedetomidine During Off-Pump Coronary Artery Bypass Grafting: GV-IN-DEX, A Randomised Controlled Trial.” Read article here.
